Flag of the European Union EU Clinical Trials Register Help

Clinical trials for Resin

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44334   clinical trials with a EudraCT protocol, of which   7366   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    15 result(s) found for: Resin. Displaying page 1 of 1.
    EudraCT Number: 2007-007759-15 Sponsor Protocol Number: CO-200-102 Start Date*: 2008-11-10
    Sponsor Name:PEPTIMMUNE Inc
    Full Title: The Effect of the Dose of PI-2301 on Safety, Tolerability, and Pharmacokinetics in Subjects with the Secondary Progressive Form of Multiple Sclerosis A double-blind, placebo-controlled, randomized,...
    Medical condition: Patients with current diagnosis of SP-MS
    Disease: Version SOC Term Classification Code Term Level
    9.1 10063400 Secondary progressive multiple sclerosis LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: HU (Completed)
    Trial results: (No results available)
    EudraCT Number: 2006-005091-41 Sponsor Protocol Number: CTU A005 Start Date*: 2007-03-16
    Sponsor Name:RIEMSER Arzneimittel AG
    Full Title: A prospective, randomized, observer-blind, reference-controlled (Provicol ®) Phase III clinical study on the efficacy and safety of Ledermix® Zementpulver after the treatment (preparation) of teeth...
    Medical condition: Teeth with dentine carious lesions without clinical symptoms of inflammation, and / or Teeth with defective filling margins
    Disease:
    Population Age: Elderly Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: (No results available)
    EudraCT Number: 2008-006968-11 Sponsor Protocol Number: AP214-CS005 Start Date*: 2009-04-21
    Sponsor Name:Action Pharma A/S
    Full Title: Pharmacokinectics of AP214 Acetate in patients undergoing cardiac surgery. A randomized, double-blind, placebo-controlled sequential ascending dose trial investigating pharmacokinetics, as well as...
    Medical condition: Action Pharma A/S is developing AP214 Acetate for the prevention of postsurgical kidney injury after thoracic aortic aneurysm repair surgery. In phase 2: Patients undergoing cardiac surgery, defin...
    Disease: Version SOC Term Classification Code Term Level
    9.1 10056675 Postoperative renal failure LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DK (Completed)
    Trial results: (No results available)
    EudraCT Number: 2007-002863-28 Sponsor Protocol Number: EPP001 Start Date*: 2007-09-26
    Sponsor Name:Guy's & St Thomas' NHS Foundation Trust
    Full Title: Investigation into the use of colestyramine as a therapy for patients with erythropoietic protoporphyria
    Medical condition: Erythropoietic protoporphyria (EPP)
    Disease: Version SOC Term Classification Code Term Level
    9.1 10015289 Erythropoietic protoporphyria LLT
    Population Age: Gender: Male, Female
    Trial protocol: GB (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2013-000723-14 Sponsor Protocol Number: 20120119 Start Date*: 2014-07-11
    Sponsor Name:Amgen Inc.
    Full Title: A Double-blind, Randomized, Placebo-Controlled, Multicenter Study to Evaluate Safety and Efficacy of Evolocumab (AMG 145) in Combination With Statin Therapy in Diabetic Subjects With Hyperlipidemia...
    Medical condition: Hyperlipidemia or mixed dyslipidemia in Diabetic Subjects
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Completed)
    Trial results: View results
    EudraCT Number: 2010-022630-92 Sponsor Protocol Number: AP214-CS007 Start Date*: 2010-11-05
    Sponsor Name:Action Pharma A/S
    Full Title: An Explorative Phase 2, Randomized, Double-Blind, Placebo-Controlled, Safety and Efficacy Trial of two Dosing Regimens of AP214 for the Prevention of Kidney Injury in Patients Undergoing Cardiac Su...
    Medical condition: Action Pharma is developing AP214 Acetate for the prevention of postsurgical kidney injury after cardiac surgery. Trial population is patients with increased risk for development of Kidney Inju...
    Disease: Version SOC Term Classification Code Term Level
    13.1 10022117 - Injury, poisoning and procedural complications 10056675 Postoperative renal failure PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DK (Completed)
    Trial results: (No results available)
    EudraCT Number: 2018-004419-32 Sponsor Protocol Number: PMS-2018-002 Start Date*: 2019-10-03
    Sponsor Name:Pharmascience Inc.
    Full Title: A Phase IIa, Proof of Concept, Randomized, Double-Blind, Dose-Finding, Cross-Over Study of the Efficacy, Safety and Tolerability of a New Enteric-Coated Cholestyramine Capsule in Adult Short Bowel ...
    Medical condition: Bile-acid induced diarrhea in adult patients with Short Bowel Syndrome (SBS)
    Disease: Version SOC Term Classification Code Term Level
    20.1 10017947 - Gastrointestinal disorders 10049416 Short-bowel syndrome PT
    20.1 10017947 - Gastrointestinal disorders 10080049 Bile acid diarrhea LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: PL (Completed)
    Trial results: View results
    EudraCT Number: 2022-003787-24 Sponsor Protocol Number: PM-CARE-PNRR-MAD-2022-12375905 Start Date*: 2023-04-20
    Sponsor Name:OSPEDALE SAN RAFFAELE
    Full Title: Precision Medicine in patients with unresectable CholAngiocarcinoma; RadioEmbolization and combined biological therapy (Single arm, multicenter phase II study investigating the efficacy and safety...
    Medical condition: Unresectable intrahepatic cholangiocarcinoma
    Disease: Version SOC Term Classification Code Term Level
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10073077 Intrahepatic cholangiocarcinoma LLT
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10008593 Cholangiocarcinoma PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2012-001365-32 Sponsor Protocol Number: 20110117 Start Date*: 2012-09-06
    Sponsor Name:Amgen Inc
    Full Title: A Double-blind, Randomized, Placebo-controlled, Multicenter Study to Evaluate Safety, Tolerability and Efficacy of AMG 145 on LDL-C in Subjects with Heterozygous Familial Hypercholesterolemia
    Medical condition: Heterozygous Familial Hypercholesterolemia
    Disease: Version SOC Term Classification Code Term Level
    15.0 10010331 - Congenital, familial and genetic disorders 10057079 Heterozygous familial hypercholesterolemia LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Completed) NL (Completed) SE (Completed) GB (Completed) DE (Completed)
    Trial results: View results
    EudraCT Number: 2009-012576-27 Sponsor Protocol Number: SORAMIC Start Date*: 2010-04-09
    Sponsor Name:Medical Faculty, University Magdeburg
    Full Title: Evaluation of Sorafenib in combination with local micro-therapy guided by Gd-EOB-DTPA enhanced MRI in patients with inoperable hepatocellular carcinoma
    Medical condition: Patients with Hepatocellular carcinoma (liver-predominant disease)
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004864 10019829 Hepatocellular carcinoma recurrent LLT
    20.0 100000004864 10019828 Hepatocellular carcinoma non-resectable LLT
    20.0 100000004864 10049010 Carcinoma hepatocellular LLT
    20.0 100000004864 10019830 Hepatocellular carcinoma resectable LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) NL (Completed) AT (Completed) ES (Completed) BE (Completed) PL (Completed) SI (Completed) IT (Completed) GB (Completed)
    Trial results: (No results available)
    EudraCT Number: 2011-001528-39 Sponsor Protocol Number: 20090158 Start Date*: 2011-07-13
    Sponsor Name:Amgen Inc
    Full Title: "A Double-blind, Radomized, Placebo-comtrolled, Multicenter Study to Evaluate Tolerability and Efficacy of AMG 145 on LDL-C in Subjects with Heterozygous Familial Hypercholesterolemia"
    Medical condition: Heterozygous familial hypercholesterolemia
    Disease: Version SOC Term Classification Code Term Level
    13.1 10010331 - Congenital, familial and genetic disorders 10057099 Heterozygous familial hypercholesterolaemia LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Completed) GB (Completed) DE (Completed) SE (Completed)
    Trial results: View results
    EudraCT Number: 2011-001529-26 Sponsor Protocol Number: 20090159 Start Date*: 2011-07-15
    Sponsor Name:Amgen Inc
    Full Title: A Randomized, Multicenter Study to Evaluate Tolerability and Efficacy of AMG 145 on LDL-C, Compared with Ezetimibe, in Hypercholesterolemic Subjects Unable to Tolerate an Effective Dose of a HMG-Co...
    Medical condition: Hypercholesterolaemia
    Disease: Version SOC Term Classification Code Term Level
    13.1 10027433 - Metabolism and nutrition disorders 10020603 Hypercholesterolaemia PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Completed) BE (Completed) SE (Completed) DK (Completed) FI (Completed)
    Trial results: View results
    EudraCT Number: 2013-000935-29 Sponsor Protocol Number: 20120332 Start Date*: 2014-02-03
    Sponsor Name:Amgen Inc.
    Full Title: A Double-blind, Randomized, Multicenter Study to Evaluate the Safety and Efficacy of AMG 145, Compared With Ezetimibe, in Hypercholesterolemic Subjects Unable to Tolerate an Effective Dose of a HMG...
    Medical condition: Hypercholesterolemia
    Disease: Version SOC Term Classification Code Term Level
    17.1 100000004861 10020604 Hypercholesterolemia LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: CZ (Completed) DE (Completed) GB (Completed) IT (Completed) DK (Completed) NL (Completed) NO (Completed)
    Trial results: View results
    EudraCT Number: 2012-001364-30 Sponsor Protocol Number: 20110116 Start Date*: 2012-09-07
    Sponsor Name:Amgen Inc
    Full Title: Title: A Double-blind, Randomized, Multicenter Study to Evaluate Safety and Efficacy of AMG 145, Compared With Ezetimibe, in Hypercholesterolemic Subjects Unable to Tolerate an Effective Dose of a ...
    Medical condition: Dyslipidemia
    Disease: Version SOC Term Classification Code Term Level
    14.1 100000004861 10020604 Hypercholesterolemia LLT
    14.1 100000004861 10058110 Dyslipidemia LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: BE (Completed) ES (Completed) DK (Completed) NL (Completed) PL (Completed) GB (Completed) DE (Completed)
    Trial results: View results
    EudraCT Number: 2014-002277-11 Sponsor Protocol Number: 20120123 Start Date*: 2015-06-23
    Sponsor Name:Amgen Inc
    Full Title: Double-blind, Randomized, Multicenter, Placebo-Controlled, Parallel Group Study to Characterize the Efficacy, Safety, and Tolerability of 24 Weeks of Evolocumab for Low Density Lipoprotein-Choleste...
    Medical condition: Heterozygous familial hypercholesterolaemia
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004850 10057079 Heterozygous familial hypercholesterolemia LLT
    Population Age: Children, Adolescents, Under 18 Gender: Male, Female
    Trial protocol: CZ (Completed) BE (Completed) ES (Completed) IT (Completed) Outside EU/EEA GR (Completed) NL (Completed) GB (Completed) AT (Completed) HU (Completed) SI (Completed) PT (Completed) PL (Completed) NO (Completed) RO (Completed)
    Trial results: View results
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Fri May 09 09:19:35 CEST 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA